ATNF: 180 Life Sciences Corp. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 2.18
Enterprise Value ($M) -0.13
Book Value ($M) -0.15
Book Value / Share -0.01
Price / Book -14.57
NCAV ($M) -1.74
NCAV / Share -0.17
Price / NCAV -1.25

Profitability (mra)
Return on Invested Capital (ROIC) -196.58
Return on Assets (ROA) -2.06
Return on Equity (ROE) -3.57

Liquidity (mrq)
Quick Ratio 0.70
Current Ratio 0.70

Balance Sheet (mrq) ($M)
Current Assets 3.37
Assets 4.96
Liabilities 5.11
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Diluted n/a
Earnings Per Share Nonrecurring Common Control Intra Entity Transactions Description n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
8 days ago 13G Armistice Capital, Llc 9.99
04-14 13D/A Feldmann Marc 3.40 -95.00

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2023-11-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q
2023-08-15 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT P
2023-05-15 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT
2023-04-28 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1)
2023-03-31 10-K Form 10-K

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-02-21 156,228 488,262 32.00
2024-02-20 148,484 656,081 22.63
2024-02-16 18,944 88,259 21.46

(click for more detail)

Similar Companies
ARTL – Artelo Biosciences, Inc. ASNS – Actelis Networks, Inc.
ASRT – Assertio Holdings, Inc. ATOS – Atossa Therapeutics, Inc.
ATXI – Avenue Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io